Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Sana Biotechnology Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.73 (market cap $141.25M), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Sana Biotechnology Inc is far larger — about 5.9× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Sana Biotechnology Inc for 23 Days on average.
| KOLD | SANA | |
|---|---|---|
Market Cap | $141.25M | $836.71M |
Volume | 5,492,367 | 4,507,444 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $5.92 |
52-Week Low | $13.58 | $2.68 |
Typical Hold Time | 10 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $24.75, down 0.36% with bearish technical signals from moving averages. The stock faces pressure from record-high natural gas production and mild weather forecasts, though geopolitical tensions in the Middle East provide some support. Technical indicators show oversold conditions with RSI at 31.97, while support levels are established at $23-$25.
The outlook remains cautious with bearish technical momentum and fundamental headwinds from oversupply concerns. Near-term catalysts include geopolitical developments and winter demand, but elevated production levels and storage capacity constraints present significant downside risks for energy sector investors.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
